AbbVie Enters into a Global License Agreement with Gubra to Develop & Commercialize GUB014295 to Treat Obesity

Shots:

• AbbVie and Gubra entered into a global license agreement to develop & commercialize GUB014295, a potential long-acting amylin analog for obesity treatment
• As per the deal, AbbVie will lead GUB014295’s global development & commercialization, whereas Gubra will get $350M upfront, up to $1.875B development, commercial, sales milestones, with tiered royalties; transaction closure is subject to regulatory approvals
• GUB-014295 is designed to activate amylin and calcitonin receptors to suppress appetite and delay gastric emptying; currently being evaluated in P-I clinical trial

Ref: AbbVie | Image: AbbVie & Gubra

Related News:- The CHMP Adopts Positive Opinion for AbbVie’s Rinvoq (Upadacitinib) to Treat Giant Cell Arteritis in Adults

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com